That kind of shot was first used during the Covid-19 pandemic, but the health secretary has been sharply critical of the ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

This marks Health Secretary Kennedy Jr's latest effort to weave vaccine scepticism into US policy. Read more at ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...

Many viruses circulate seasonally, picking up as the weather cools in the fall and winter. So it’s true that fewer people get ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Now, it’s worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS.